Statistics from Altmetric.com
We read with great interest the article by Sabbagh et al 1 published in the Annals of the Rheumatic Diseases. We congratulate the authors for their accuracy and the exhaustive data presented, which clearly demonstrate the importance of anti-Ro52 autoantibodies in disease monitoring, management and prognosis in patients with juvenile myositis. We would like, however, to highlight some key points.
First, in this study,1 the patients with juvenile myositis including juvenile dermatomyositis (JDM), juvenile polymyositis (JPM) and juvenile connective tissue disease–myositis (JCTM) overlap are a highly heterogeneous population. In particular, JCTM added a great heterogeneity to the study population. In reality, there has been still controversy on considering CTM as a distinct entity or rather a complication …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.